EP0893997A1 — Paroxetine in treatment of depression
Assigned to SmithKline Beecham Ltd · Expires 1999-02-03 · 27y expired
What this patent protects
Paroxetine or a pharmaceutically acceptable salt thereof is used for treating and/or preventing the following depression sub-types: adolescent, bipolar, elderly, major, minor, moderate, recurrent, refractory, severe unipolar, dysthymia, post natal, double depression, post psychot…
USPTO Abstract
Paroxetine or a pharmaceutically acceptable salt thereof is used for treating and/or preventing the following depression sub-types: adolescent, bipolar, elderly, major, minor, moderate, recurrent, refractory, severe unipolar, dysthymia, post natal, double depression, post psychotic, post viral, bereavement, primary, secondary, post traumatic stress disorder and depression associated with withdrawal from substances of abuse such as alcohol, nicotine, cocaine, heroin, benzodiazepines, in human or non-human animals. A preferred salt of paroxetine is the hydrochloride, particularly in crystalline form, such as the hemi-hydrate.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.